TABLE 6.
Time (day or peak) | Results for different doses (mg)
|
|||||||
---|---|---|---|---|---|---|---|---|
0.1
|
0.4
|
1.0
|
1.5
|
|||||
Geometric mean fold rise | % >2-fold risef | Geometric mean fold rise | % >2-fold rise | Geometric mean fold rise | % >2-fold rise | Geometric mean fold rise | % >2-fold rise | |
14 | 1.07 | 20 | 1.19a | 11a | 1.42 | 50 | 1.48 | 40 |
23 | 0.80 | 20 | 1.62a | 33a | 2.11 | 60 | 0.71b | 17b |
42 | 0.70 | 0 | 0.85a | 10a | 1.03 | 20 | 1.13 | 30 |
70 | 0.65 | 0 | 1.10 | 10 | 1.59c | 50 | 1.48d | 40 |
Peake | 1.35 | 20 | 2.07 | 33 | 3.36 | 70 | 2.37 | 70 |
Subjects were evaluable.
Only six subjects were evaluable.
P = 0.10 for the comparison of the geometric mean fold rise to 1, i.e., no change.
P < 0.06 for the comparison of the geometric mean fold rise to 1, i.e., no change.
Includes the strongest response for each subject with at least three postimmunization values.
Percentage by which result exceeds twofold increase is given.